EGFR and neoplasm: Among the genomic alterations present in cfDNA and tumor DNA (tDNA) in high-risk stage 3 and 4 breast cancer patients, TP53 and PIK3CA mutations, along with epidermal growth factor receptor (EGFR) and ERBB2 amplifications, emerged as the most common.